Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy
Diana Finzi, Monika Hermankova, Theodore Pierson, Lucy M. Carruth, Christopher Buck, Richard E. Chaisson, Thomas C. Quinn, Karen Chadwick, Joseph Margolick, Ronald Brookmeyer, Joel Gallant, Martin Markowitz, David D. Ho, Douglas D. Richman, Robert F. Siliciano- Multidisciplinary
The hypothesis that quiescent CD4+T lymphocytes carrying proviral DNA provide a reservoir for human immunodeficiency virus–type 1 (HIV-1) in patients on highly active antiretroviral therapy (HAART) was examined. In a study of 22 patients successfully treated with HAART for up to 30 months, replication-competent virus was routinely recovered from resting CD4+T lymphocytes. The frequency of resting CD4+T cells harboring latent HIV-1 was low, 0.2 to 16.4 per 106cells, and, in cross-sectional analysis, did not decrease with increasing time on therapy. The recovered viruses generally did not show mutations associated with resistance to the relevant antiretroviral drugs. This reservoir of nonevolving latent virus in resting CD4+T cells should be considered in deciding whether to terminate treatment in patients who respond to HAART.